Alpine Immune Sciences, Inc.

Informe acción NasdaqGM:ALPN

Capitalización de mercado: US$4.5b

Salud financiera de hoja de balance de Alpine Immune Sciences

Salud financiera controles de criterios 6/6

Alpine Immune Sciences tiene un patrimonio de los accionistas total de $332.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $373.6M y $40.9M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$305.66m
PatrimonioUS$332.70m
Total pasivoUS$40.94m
Activos totalesUS$373.65m

Actualizaciones recientes sobre salud financiera

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

May 11
Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Sep 20

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($308.3M) de ALPN superan a sus pasivos a corto plazo ($32.2M).

Pasivo a largo plazo: Los activos a corto plazo de ALPN ($308.3M) superan a sus pasivos a largo plazo ($8.7M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ALPN está libre de deudas.

Reducción de la deuda: ALPN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 6.6%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALPN tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ALPN dispone de suficiente cash runway para 2.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 21.4% cada año.


Descubre empresas con salud financiera